101 related articles for article (PubMed ID: 19650815)
1. Varenicline increases striatal dopamine D(2/3) receptor binding in rats.
Crunelle CL; Miller ML; de Bruin K; van den Brink W; Booij J
Addict Biol; 2009 Sep; 14(4):500-2. PubMed ID: 19650815
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats.
Crunelle CL; Schulz S; de Bruin K; Miller ML; van den Brink W; Booij J
Eur Neuropsychopharmacol; 2011 Feb; 21(2):205-10. PubMed ID: 21130610
[TBL] [Abstract][Full Text] [Related]
3. Varenicline increases in vivo striatal dopamine D2/3 receptor binding: an ultra-high-resolution pinhole [123I]IBZM SPECT study in rats.
Crunelle CL; de Wit TC; de Bruin K; Ramakers RM; van der Have F; Beekman FJ; van den Brink W; Booij J
Nucl Med Biol; 2012 Jul; 39(5):640-4. PubMed ID: 22261145
[TBL] [Abstract][Full Text] [Related]
4. Striatal dopamine D2/D3 receptor availability in male smokers.
Yang YK; Yao WJ; McEvoy JP; Chu CL; Lee IH; Chen PS; Yeh TL; Chiu NT
Psychiatry Res; 2006 Jan; 146(1):87-90. PubMed ID: 16343861
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
[TBL] [Abstract][Full Text] [Related]
6. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
Mihalak KB; Carroll FI; Luetje CW
Mol Pharmacol; 2006 Sep; 70(3):801-5. PubMed ID: 16766716
[TBL] [Abstract][Full Text] [Related]
7. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
[TBL] [Abstract][Full Text] [Related]
8. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers.
Loughead J; Ray R; Wileyto EP; Ruparel K; Sanborn P; Siegel S; Gur RC; Lerman C
Biol Psychiatry; 2010 Apr; 67(8):715-21. PubMed ID: 20207347
[TBL] [Abstract][Full Text] [Related]
9. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
10. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system.
Ericson M; Löf E; Stomberg R; Söderpalm B
J Pharmacol Exp Ther; 2009 Apr; 329(1):225-30. PubMed ID: 19126781
[TBL] [Abstract][Full Text] [Related]
11. No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys.
Vermeulen RJ; Drukarch B; Verhoeff NP; Goosen C; Sahadat MC; Wolters EC; van Royen EA; Stoof JC
Synapse; 1994 Jun; 17(2):115-24. PubMed ID: 7916490
[TBL] [Abstract][Full Text] [Related]
12. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review.
Crunelle CL; Miller ML; Booij J; van den Brink W
Eur Neuropsychopharmacol; 2010 Feb; 20(2):69-79. PubMed ID: 19959340
[TBL] [Abstract][Full Text] [Related]
13. [Varenicline--a new chance for smokers?].
Goniewicz ML; Koszowski B; Czogała J; Sobczak A
Przegl Lek; 2007; 64(10):899-902. PubMed ID: 18409337
[TBL] [Abstract][Full Text] [Related]
14. [Effects of hemantane on the main subtypes of dopamine receptors in the rat striatum ex vivo].
Abaimov DA; Zimin IA; Kovalev GI
Eksp Klin Farmakol; 2008; 71(1):18-21. PubMed ID: 18365481
[TBL] [Abstract][Full Text] [Related]
15. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
Coe JW; Brooks PR; Vetelino MG; Wirtz MC; Arnold EP; Huang J; Sands SB; Davis TI; Lebel LA; Fox CB; Shrikhande A; Heym JH; Schaeffer E; Rollema H; Lu Y; Mansbach RS; Chambers LK; Rovetti CC; Schulz DW; Tingley FD; O'Neill BT
J Med Chem; 2005 May; 48(10):3474-7. PubMed ID: 15887955
[TBL] [Abstract][Full Text] [Related]
16. Lack of sex differences in striatal dopamine D2 receptor binding in drug-naive schizophrenic patients: an IBZM-SPECT study.
Parellada E; Lomeña F; Catafau AM; Bernardo M; Font M; Fernández-Egea E; Pavía J; Gutierrez F
Psychiatry Res; 2004 Jan; 130(1):79-84. PubMed ID: 14972370
[TBL] [Abstract][Full Text] [Related]
17. Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
Bordia T; Hrachova M; Chin M; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2012 Aug; 342(2):327-34. PubMed ID: 22550286
[TBL] [Abstract][Full Text] [Related]
18. Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area.
Reperant C; Pons S; Dufour E; Rollema H; Gardier AM; Maskos U
Neuropharmacology; 2010 Feb; 58(2):346-50. PubMed ID: 19887076
[TBL] [Abstract][Full Text] [Related]
19. Effect of desipramine during infancy and preweanling on dorsal striatal dopamine D1 and D2 receptor binding in adolescence in the rat.
Hilakivi I; Rinne J; Marjamäki P
Pol J Pharmacol; 1999; 51(4):311-6. PubMed ID: 10540962
[TBL] [Abstract][Full Text] [Related]
20. A comparison of brain and behavioral effects of varenicline and nicotine in rats.
King J; Huang W; Chen W; Heffernan M; Shields J; Rane P; Bircher R; DiFranza JR
Behav Brain Res; 2011 Sep; 223(1):42-7. PubMed ID: 21527291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
